BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Apr 16, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) 10% Owner Jack Bendheim Sells Shares
What Happened
- Jack Bendheim, a 10% owner and director/officer of Phibro Animal Health Corp. (PAHC), sold a total of 21,120 shares in multiple open-market transactions between April 14–16, 2026, generating approximately $1,201,594 in gross proceeds. Individual sales reported: 6,548 sh @ $59.03 ($386,553); 492 sh @ $59.69 ($29,369); 2,623 sh @ $56.27 ($147,594); 3,618 sh @ $57.21 ($206,985); 799 sh @ $58.11 ($46,432); 5,190 sh @ $54.56 ($283,141); 1,850 sh @ $54.88 ($101,520).
- On April 16, 2026, the filing also shows conversion activity of 100,000 shares (reported as derivative conversions at $0.00). Footnote information indicates Class B common stock is convertible into Class A on a one-for-one basis.
Key Details
- Transaction dates: April 14–16, 2026. Filing date: April 16, 2026 (period of report begins Apr 14).
- Sales totaled 21,120 shares for about $1.20M in aggregate proceeds.
- Conversion activity: 100,000 shares acquired and a corresponding 100,000-share derivative disposition reported at $0.00 on April 16 (reflects class conversion per footnote).
- Pricing: some sale entries are weighted-average prices covering multiple executions and small price ranges (see filing footnotes for exact ranges); the filer offers to provide per-price breakdown on request.
- Reported holdings after the transactions are not specified in the Form 4 filing.
- Footnotes: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC (Dec 11, 2025). Some securities are directly held by Bendheim and some are held by BFI (Bendheim exercises voting/dispositive power over BFI).
- Timeliness: Filing appears timely (reporting period Apr 14; filed Apr 16); no late-filing indication was shown.
Context
- This filing is dominated by open-market sales (routine liquidity or portfolio management) and a class-conversion of shares (Class B to Class A). Conversion entries at $0 reflect the mechanical conversion of share class rather than a cash purchase.
- As a 10% owner and director with holdings both directly and via BFI, Bendheim’s transactions include sales under a pre-established 10b5‑1 plan — a common method for insiders to sell shares according to a pre-set schedule. These sales do not by themselves indicate his personal view of the company’s prospects.
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-04-14$59.03/sh−6,548$386,553→ 31,572 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-04-14$59.69/sh−492$29,369→ 31,080 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-04-15$56.27/sh−2,623$147,594→ 28,457 total(indirect: See) - Sale
Class A Common Stock
[F1][F6][F3]2026-04-15$57.21/sh−3,618$206,985→ 24,839 total(indirect: See) - Sale
Class A Common Stock
[F1][F7][F3]2026-04-15$58.11/sh−799$46,432→ 24,040 total(indirect: See) - Conversion
Class A Common Stock
[F8][F3]2026-04-16+100,000→ 124,040 total(indirect: See) - Sale
Class A Common Stock
[F1][F9][F3]2026-04-16$54.56/sh−5,190$283,141→ 118,850 total(indirect: See) - Sale
Class A Common Stock
[F1][F10][F3]2026-04-16$54.88/sh−1,850$101,520→ 117,000 total(indirect: See) - Conversion
Class B Common Stock
[F8][F3]2026-04-16−100,000→ 19,496,034 total(indirect: See)Exercise: $0.00→ Class A Common Stock (100,000 underlying)
Holdings
- 16,840
Class A Common Stock
[F11]
Footnotes (11)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.
- [F10]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.80 to $54.985.
- [F11]The reported securities are directly held by Jack Bendheim.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.63 to $59.61. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5, 6, 7, 9 and 10.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.83.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.87 to $56.73.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.88.
- [F7]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.92 to $58.22.
- [F8]Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.
- [F9]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.80 to $54.79.